United Therapeutics Corporation (UTHR): Price and Financial Metrics


United Therapeutics Corporation (UTHR)

Today's Latest Price: $135.54 USD

0.47 (0.35%)

Updated Nov 27 1:00pm

Add UTHR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

UTHR Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.37 for UNITED THERAPEUTICS Corp; that's greater than it is for just 19.03% of US stocks.
  • With a year-over-year growth in debt of -20%, UNITED THERAPEUTICS Corp's debt growth rate surpasses only 15.09% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, UNITED THERAPEUTICS Corp is reporting a growth rate of -703.98%; that's higher than only 2.82% of US stocks.
  • If you're looking for stocks that are quantitatively similar to UNITED THERAPEUTICS Corp, a group of peers worth examining would be ZNGA, EXK, HLIT, GEOS, and GIGA.
  • Visit UTHR's SEC page to see the company's official filings. To visit the company's web site, go to www.unither.com.

UTHR Stock Price Chart Interactive Chart >

Price chart for UTHR

UTHR Price/Volume Stats

Current price $135.54 52-week high $144.26
Prev. close $135.07 52-week low $75.58
Day low $134.29 Volume 113,200
Day high $135.85 Avg. volume 509,672
50-day MA $121.04 Dividend yield N/A
200-day MA $111.67 Market Cap 6.02B

United Therapeutics Corporation (UTHR) Company Bio


United Therapeutics develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension. The company was founded in 1996 and is based in Silver Spring, Maryland.

UTHR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$135.54$244.19 80%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for UNITED THERAPEUTICS Corp. To summarize, we found that UNITED THERAPEUTICS Corp ranked in the 60th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 80.5% on a DCF basis. The most interesting components of our discounted cash flow analysis for UNITED THERAPEUTICS Corp ended up being:

  • As a business, UTHR is generating more cash flow than 73.69% of positive cash flow stocks in the Healthcare.
  • UTHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 31.8% of tickers in our DCF set.
  • UNITED THERAPEUTICS Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 21.66. This coverage rate is greater than that of 87.71% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%76%
1%78%
2%80%
3%81%
4%83%
5%85%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as UTHR, try ANIP, LH, HCSG, DGX, and PBH.


UTHR Latest News Stream


Event/Time News Detail
Loading, please wait...

UTHR Latest Social Stream


Loading social stream, please wait...

View Full UTHR Social Stream

Latest UTHR News From Around the Web

Below are the latest news stories about UNITED THERAPEUTICS Corp that investors may wish to consider to help them evaluate UTHR as an investment opportunity.

CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant

REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a…

PR Newswire | September 21, 2020

United Therapeutics Corporation Appoints Linda Maxwell to Its Board of Directors

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the appointment of Linda Maxwell, M.D. to its Board of Directors as an independent director, effective as of September 10, 2020. Dr. Maxwell…

PR Newswire | September 11, 2020

United Therapeutics Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Tyvaso® For Pulmonary Hypertension Associated With Interstitial Lung Disease

/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for review the…

PR Newswire | August 17, 2020

10 Biggest Biotechnology Companies

With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.

Yahoo | July 30, 2020

United Therapeutics (UTHR) Q2 Earnings In Line, Sales Beat

United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

Yahoo | July 30, 2020

Read More 'UTHR' Stories Here

UTHR Price Returns

1-mo 0.98%
3-mo 26.72%
6-mo 10.14%
1-year 46.91%
3-year 4.27%
5-year -14.75%
YTD 53.88%
2019 -19.12%
2018 -26.39%
2017 3.15%
2016 -8.42%
2015 20.94%

Continue Researching UTHR

Want to see what other sources are saying about UNITED THERAPEUTICS Corp's financials and stock price? Try the links below:

UNITED THERAPEUTICS Corp (UTHR) Stock Price | Nasdaq
UNITED THERAPEUTICS Corp (UTHR) Stock Quote, History and News - Yahoo Finance
UNITED THERAPEUTICS Corp (UTHR) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8957 seconds.